<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027221</url>
  </required_header>
  <id_info>
    <org_study_id>IMPACT2010</org_study_id>
    <nct_id>NCT01027221</nct_id>
  </id_info>
  <brief_title>Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer</brief_title>
  <acronym>IMPACT2010</acronym>
  <official_title>Randomised Phase I/II Trial in Order to Evaluate the Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Neoadjuvant Low-Dose-Radiation Therapy in Primarily Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Principal purpose of the study is the determination of an active local external beam
      radiotherapy dose leading to a maximum number of tumor infiltrating T-cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumoral activity</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>local control and recurrence patterns of pancreatic cancer relative to a standard as seen in historical controls</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical morbidity in patients undergoing pancreatic resection who received this protocol treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequencies of tumor-reactive T-cells in blood and bone marrow</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of migration-relevant adhesion molecules on tumor endothelial cells</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of proinflammatory cytokines and activation-dependent, immune-associated transcriptionally factors in tumors and blood</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life according to the EORTC QoL questionnaire after 6, 12, 18 and 24 months</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primarily Resectable Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>0</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>primarily resectable pancreatic cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0,5 Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant Radiation of 0,5 Gy two days before resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant Radiation of 2 Gy 2 days before resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Gy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant Radiation of 5 Gy 2 days before resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant photon radiation</intervention_name>
    <description>single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection</description>
    <arm_group_label>0,5 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant photon radiation</intervention_name>
    <description>single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection</description>
    <arm_group_label>2 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant photon radiation</intervention_name>
    <description>single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection</description>
    <arm_group_label>5 Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radiological diagnosis of resectable pancreatic carcinoma is required prior to
             treatment. Potentially resectable is defined as no extrapancreatic disease, no
             evidence (on CT) of involvement of the celiac axis or superior mesenteric artery, no
             evidence (on CT or MRI) of occlusion of the superior mesenteric vein or superior
             mesenteric-portal venous confluence.

          -  No evidence of metastatic disease as determined by chest CT scan, abdominal CT scan
             (or MRI)

          -  18 years of age or older

          -  American Society of Anesthesiologists (ASA)- Performance status of 1 to 3

          -  Women of child bearing potential must practice adequate contraception and refrain from
             breast feeding. Female patients must have a negative pregnancy test within 7 days of
             treatment

          -  Informed consent

        Exclusion Criteria:

          -  Locally irresectable pancreatic cancer

          -  distant metastases

          -  medically unfit for surgery

          -  Pregnant or lactating women

          -  prior chemotherapy or radiation treatment

          -  Other serious uncontrolled medical conditions that the investigator feels might
             compromise study participation

          -  Unwillingness to participate or inability to comply with the protocol for the duration
             of the study

          -  Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment,
             without complete recovery

          -  Participation in other interventional trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter E. Huber, Prof. PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Cancer Research Centre and Clinic for Radiation Oncology of the University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic for General, Visceral and Transplantation Surgery</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christin Tjaden, Dr. med.</last_name>
      <email>Christine.Tjaden@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>German Cancer Research Center</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Ernst Huber, Prof. PhD MD</last_name>
      <phone>+49-6221-422515</phone>
      <email>p.huber@dkfz.de</email>
    </contact>
    <contact_backup>
      <last_name>Niels Nicolay, Dr. med.</last_name>
      <phone>+49 6221 42 2587</phone>
      <email>n.nicolay@dkfz-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Peter E. Huber, Prof. PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chrstin Tjaden, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Rieken, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Beckhove, PhD MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Dose Radiation</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>Immunostimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

